1109 related articles for article (PubMed ID: 27243629)
1. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
3. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.
Fraser I; Burger J; Lubbe M; Dranitsaris G; Sonderup M; Stander T
Pharmacoeconomics; 2016 Apr; 34(4):403-17. PubMed ID: 26666639
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US.
Zhang S; Bastian ND; Griffin PM
BMC Gastroenterol; 2015 Aug; 15():98. PubMed ID: 26239358
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan.
Kawaguchi I; Chayama K; Gonzalez YS; Virabhak S; Mitchell D; Yuen C; Kumada H
Adv Ther; 2020 Jan; 37(1):457-476. PubMed ID: 31808054
[TBL] [Abstract][Full Text] [Related]
8. Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Chen GF; Wei L; Chen J; Duan ZP; Dou XG; Xie Q; Zhang WH; Lu LG; Fan JG; Cheng J; Wang GQ; Ren H; Wang JP; Yang XX; Jia ZS; Fu QC; Wang XJ; Shang J; Zhang YX; Han Y; Du N; Shao Q; Ji D; Li F; Li B; Liu JL; Niu XX; Wang C; Wu V; Wong A; Wang YD; Hou JL; Jia JD; Zhuang H; Lau G
PLoS One; 2016; 11(6):e0155934. PubMed ID: 27276081
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection.
Younossi ZM; Park H; Saab S; Ahmed A; Dieterich D; Gordon SC
Aliment Pharmacol Ther; 2015 Mar; 41(6):544-63. PubMed ID: 25619871
[TBL] [Abstract][Full Text] [Related]
10. New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.
Beckman AL; Bilinski A; Boyko R; Camp GM; Wall AT; Lim JK; Wang EA; Bruce RD; Gonsalves GS
Health Aff (Millwood); 2016 Oct; 35(10):1893-1901. PubMed ID: 27702964
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Elsisi GH; Aburawash A; Waked E
Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
[TBL] [Abstract][Full Text] [Related]
12. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
13. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Ward T; Webster S; Mishina S; McEwan P; Wygant G; Wang F
Value Health Reg Issues; 2017 May; 12():1-6. PubMed ID: 28648305
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
15. Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Chidi AP; Bryce CL; Donohue JM; Fine MJ; Landsittel DP; Myaskovsky L; Rogal SS; Switzer GE; Tsung A; Smith KJ
Value Health; 2016 Jun; 19(4):326-34. PubMed ID: 27325324
[TBL] [Abstract][Full Text] [Related]
16. Modeling the fiscal costs and benefits of alternative treatment strategies in the United Kingdom for chronic hepatitis C.
Connolly MP; Kotsopoulos N; Ustianowski A
J Med Econ; 2018 Jan; 21(1):19-26. PubMed ID: 28830254
[TBL] [Abstract][Full Text] [Related]
17. Drug Pricing Evolution in Hepatitis C.
Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
[TBL] [Abstract][Full Text] [Related]
18. Drug pricing: still a barrier to elimination of HCV.
The Lancet Gastroenterology Hepatology
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):813. PubMed ID: 30507462
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: Treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
Buti M; Domínguez-Hernández R; Oyagüez I; Casado MA; Esteban R
J Viral Hepat; 2017 Sep; 24(9):750-758. PubMed ID: 28273410
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Case for Eminent Domain of Hepatitis C Virus Treatment Patents.
Mattingly Ii TJ; Heil EL; Hoke KS
J Health Care Poor Underserved; 2017; 28(2):621-625. PubMed ID: 28529212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]